Business
Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium
CHICAGO, December 09, 2025--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas.
About this update from Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5e449ba1b44eacf51efff557e29d6150"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YV1WbaYs4l84KCGJDP_y2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5e449ba1b44eacf51efff557e29d6150","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0CWSvCBtiOwp38HI.uYVow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5e449ba1b44eacf51efff557e29d6150","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, December 09, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas.","length":386,"tagName":"p"},{"type":"text","content":""This year at SABCS, our research highlights the power of multimodal data to help unravel the complexity of breast cancer," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "By integrating genomic, transcriptomic, and real-world clinical data, we are moving beyond broad disease classifications to uncover specific molecular drivers of progression and resistance. These insights are essential for pinpointing patient populations who may benefit from novel therapies and for optimizing treatment strategies to ultimately improve outcomes for those with advanced disease."","length":607,"tagName":"p"},{"type":"text","content":"Tempus will highlight its latest scientific and clinical research findings via ten poster presentations:","length":104,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Integrative Modeling of Multimodal Real-World Data for Improved Risk Stratification of First-Line CDK4/6 Inhibitor Outcomes in Patients with Estrogen Receptor (ER)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer","length":254,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[...